Douglas Lane & Associates LLC reduced its position in Zoetis Inc (NYSE:ZTS) by 34.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,745 shares of the company’s stock after selling 38,972 shares during the period. Douglas Lane & Associates LLC’s holdings in Zoetis were worth $6,661,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Gables Capital Management Inc. purchased a new stake in shares of Zoetis in the first quarter worth about $109,000. Sun Life Financial INC lifted its position in shares of Zoetis by 604.3% in the second quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after buying an additional 1,124 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Zoetis by 3,033.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after buying an additional 1,365 shares in the last quarter. Fort L.P. purchased a new stake in shares of Zoetis in the second quarter worth about $121,000. Finally, Private Capital Group LLC lifted its position in shares of Zoetis by 118.4% in the first quarter. Private Capital Group LLC now owns 1,529 shares of the company’s stock worth $128,000 after buying an additional 829 shares in the last quarter. Institutional investors own 89.76% of the company’s stock.
Shares of ZTS stock opened at $89.63 on Thursday. Zoetis Inc has a 1 year low of $63.03 and a 1 year high of $94.31. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50. The company has a market cap of $44.12 billion, a price-to-earnings ratio of 37.35, a P/E/G ratio of 1.74 and a beta of 1.01.
In other news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $92.03, for a total value of $184,060.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Glenn David sold 16,385 shares of the stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $92.20, for a total value of $1,510,697.00. Following the completion of the sale, the chief financial officer now owns 29,234 shares in the company, valued at $2,695,374.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 213,467 shares of company stock worth $19,502,725. Company insiders own 0.35% of the company’s stock.
A number of research firms recently commented on ZTS. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Friday, July 27th. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 target price on shares of Zoetis in a research report on Thursday, August 2nd. Stifel Nicolaus upped their price objective on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Finally, Bank of America upped their price objective on Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $91.73.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: How is an ETF different from a mutual fund?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.